Allogenic expanded adipose-derived stem cell therapy (UnicoCell)

N/A

Report date: 2022/09/05 20:00:48

Base Information

Drug NameAllogenic expanded adipose-derived stem cell therapy (UnicoCell)

Drug Alias NameElixcyteADSC-UnicoCell

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Adipose-derivedCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionCell replacementsImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsRenal Insufficiency, ChronicOsteoarthritis, Knee

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesUnicocell Biomed Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesUnicocell Biomed Co Ltd

Inactive CompaniesN/A

Active IndicationsRenal Insufficiency, ChronicOsteoarthritis, Knee

Inactive IndicationsN/A

Other Information

ATC CodeN/A